UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
October 10, 2008
Date of Report (Date of earliest event reported)
ABBOTT LABORATORIES
(Exact name of registrant as specified in its charter)
|
Illinois |
|
1-2189 |
|
36-0698440 |
|
(State or other Jurisdiction |
|
(Commission File Number) |
|
(I.R.S. Employer |
100 Abbott Park Road
Abbott Park, Illinois 60064-6400
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (847) 937-6100
Check the appropriate box if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 - Election of Director
On October 10, 2008, Robert J. Alpern, M.D., Dean of the Yale School of Medicine, was named to the Abbott Board of Directors, effective immediately.
Item 5.03 – Amendment to Articles of Incorporation or Bylaws; Changes in Fiscal Year
On October 10, 2008, Abbott Laboratories’ Board of Directors amended the first sentence of Article III, Section 2 of Abbott’s by-laws to provide that Abbott’s Board of Directors shall consist of fourteen persons, effective as of October 10, 2008. Abbott’s by-laws previously provided that the Board of Directors consisted of thirteen persons.
Item 9.01 – Financial Statements and Exhibits
(d) Exhibits
|
Exhibit No. |
|
Exhibit |
|
|
|
|
|
3.1 |
|
By-Laws of Abbott Laboratories, as amended and restated effective October 10, 2008 |
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Abbott Laboratories |
|
|
|
|
|
|
Date: October 17, 2008 |
|
|
|
|
|
|
|
|
By: |
/s/ Thomas C. Freyman |
|
|
|
Thomas C. Freyman |
|
|
|
Executive Vice President, |
|
|
|
Finance and Chief Financial |
2
Exhibit Index
|
Exhibit No. |
|
Exhibit |
|
|
|
|
|
3.1 |
|
By-Laws of Abbott Laboratories, as amended and restated effective October 10, 2008 |
3